Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-center open-label dabrafenib study in previously treated BRAF V600E-mutated hairy cell leukemia
2014-001379-29Phase 2Active
- Sponsor
- Dipartimento di Medicina
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib in hairy cell leukemia (HCL), sponsored by Dipartimento di Medicina. Primary endpoint: Overall response rate. Started Apr 2014; status: active.
02
Drugs
dabrafenib + trametinib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on 2014-001379-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001379-29.